

## Cytokeratin 7 & 8 clone CAM 5.2

### Instructions for Use


#### Specification:

The Cytokeratin 7 & 8 antibody has a primary reactivity with human cytokeratin proteins that correspond to Moll's peptide #7 (cytokeratin 7) and Moll's peptide #8 (cytokeratin 8), 54 and 53 kilodaltons (kDa), respectively. <sup>1-4</sup>

The cytokeratin 7 and 8 antigens are present on secretory epithelia of normal human tissue, but not on stratified squamous epithelium.<sup>1</sup> The Cytokeratin 7 & 8 antibody stains most epithelial-derived tissue, including liver, renal tubular epithelium, and hepatocellular and renal cell carcinomas. The Cytokeratin 7 & 8 antibody might not react with some squamous cell carcinomas. <sup>2,5,6</sup>

#### Availability:

Catalog No.	Contents	Volume
ILM84911-C01	Cytokeratin 7 & 8	0,1 ml concentrate
ILM84911-C05	Cytokeratin 7 & 8	0,5 ml concentrate
ILM84911-C1	Cytokeratin 7 & 8	1,0 ml concentrate



**Intended use:** For Research Use Only

**Reactivity:** Human

**Clone:** CAM 5.2

**Species of origin:** Mouse

**Isotype:** IgG<sub>2a</sub>

**Control Tissue:** Adenocarcinomas, pancreas, prostate, salivary gland

**Staining:** Cytoplasmic

**Immunogen:** Human colorectal carcinoma cell line HT29

**Presentation:** Mouse Monoclonal antibody in PBS, containing 1% BSA and 0.09% sodium azide.

#### Application and suggested dilutions:

Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, for 20 minutes or Protease K treatment for 10 min at 37°C, is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:400-1:800)

The optimal dilution for a specific application should be determined by the investigator.

**Note:** Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

**Storage & Stability:** Store at 2-8 °C. Do not use after expiration date printed on the vial.

#### References:

- 1) Moll R, et al, Cell. 1982; 31:11-24.
- 2) Makin C, et al, J Clin Pathol. 1984; 37:975.
- 3) Cooper D, et al, Lab Invest. 1985; 52:243-256.
- 4) Smedts F, et al, Am J Pathol. 1990; 136:657-667.
- 5) Battifora H. Progress in Surgical Pathology. Vol 8: Field & Wood Medical Publishers; 1990:1-15.
- 6) Johnson A, et al, Br J Cancer. 1985; 52:159-165.
- 7) Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
- 8) Centers for Disease Control. MMWR. 1988; 37:377-388.